Mar 14, 2022
SAN DIEGO, March 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that Carissa Rollins will join the company as Chief Information Officer on March 14, 2022. Rollins brings over 30 years of business technology transformation and digital and consumerization strategy experience. Rollins will report to Chief Executive Officer, Francis deSouza.
Most recently, Rollins was the Chief Information Officer at UnitedHealthcare. She was responsible for the strategy, roadmap, and technology investments supporting the commercial, Medicare and retirement, and government programs technology business portfolios. Before UnitedHealthcare, Rollins held executive and senior leadership positions at Gander Mountain, Kohl's Corporation, Manpower Global, and Miller-Coors.
"We are delighted to have Carissa join the leadership team at Illumina," said Francis deSouza, Illumina's Chief Executive Officer. "Carissa has an excellent track record of leveraging IT innovation at scale to deliver great customer and employee experiences. We're looking forward to working together to accelerate toward a future of personalized medicine for patients around the world."
"I look forward to joining the Illumina team and building upon the high-performance teams, ensuring that key stakeholders have a continuously improved experience with IT services and support," shares Rollins. "For me, by focusing on our talent, the technology innovation will continue to create space to unlock the power of the genome."
Rollins has served on the Board of Directors for the YWCA, Minneapolis, and is currently the Board Chair. She also serves on the Grand Canyon Conservancy board and the T-Mobile advisory board. Rollins holds a B.S. in Management Information Systems and an MBA from Marquette University.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations once deployed, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-welcomes-carissa-rollins-as-chief-information-officer-301501578.html
SOURCE Illumina, Inc.